Cargando…

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis

A man with relapsing multiple sclerosis, treated with fingolimod 0.5 mg/d for 15 months, developed acute lymphoblastic leukemia and died 4 months after immune ablation and bone marrow allograft, from graft versus host disease. To our knowledge, this is the first case of acute lymphoblastic leukemia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohan, Stanley, Godwin, John, Gaedeke, Leah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586908/ https://www.ncbi.nlm.nih.gov/pubmed/26425635 http://dx.doi.org/10.1177/2324709615575551

Ejemplares similares

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
por: Fukai, Ryoko, et al.
Publicado: (2019)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Yavari, Fatemeh, et al.
Publicado: (2021)

Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod
por: Song, Zi-Ye, et al.
Publicado: (2015)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
por: Hunter, Samuel F., et al.
Publicado: (2015)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis
por: Portaccio, Emilio
Publicado: (2011)

Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis
por: Druart, Charlotte, et al.
Publicado: (2017)

Cardiac repolarization during fingolimod treatment in patients with relapsing–remitting multiple sclerosis
por: Laiho, Aapo, et al.
Publicado: (2018)

Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran
por: Ouspid, Elham, et al.
Publicado: (2018)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

A randomized study to evaluate the effect of exercise on fatigue in people with relapsing–remitting multiple sclerosis treated with fingolimod
por: Mäurer, M, et al.
Publicado: (2018)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Initial Presentation of Acute Lymphoblastic Leukemia with Osteoporosis and Multiple Spontaneous Bone Fractures
por: Cohan, N, et al.
Publicado: (2011)

Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America
por: Correale, Jorge, et al.
Publicado: (2015)

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
por: Cohen, Jeffrey A., et al.
Publicado: (2019)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Testicular relapse of acute lymphoblastic leukemia()
por: Carolan, Alexandra, et al.
Publicado: (2023)

The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod
por: Cohen, Jeffrey A, et al.
Publicado: (2019)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients
por: Farrokhi, Mehrdad, et al.
Publicado: (2015)

COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy
por: Fujii, Chihiro, et al.
Publicado: (2016)

Real‐life long‐term effectiveness of fingolimod in Swiss patients with relapsing‐remitting multiple sclerosis
por: Zecca, C., et al.
Publicado: (2018)

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
por: Izquierdo, Guillermo, et al.
Publicado: (2017)

Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
por: Naser Moghadasi, Abdoreza, et al.
Publicado: (2020)

Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
por: Comi, Giancarlo, et al.
Publicado: (2020)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021)

Pericardial Relapse of Acute Lymphoblastic Leukemia (ALL)
por: Maslov, Diana V., et al.
Publicado: (2021)

Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis
por: Racca, Vittorio, et al.
Publicado: (2019)

A concise synthesis of Fingolimod: an orally available drug for treating multiple sclerosis
por: Yan, Ning, et al.
Publicado: (2015)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Foerch, Christian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m0ei11ogndr4csar8gtjvr57mq